| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Asbestos history and use
|
Frank, Arthur L.
|
|
|
193 |
C |
p.
|
artikel
|
| 2 |
Brain metastases in clinical trial participants with KRAS-mutated advanced non-small cell lung cancer receiving docetaxel: Pooled data analysis
|
Aptekar, Jacob
|
|
|
193 |
C |
p.
|
artikel
|
| 3 |
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trial
|
Baramidze, Ana
|
|
|
193 |
C |
p.
|
artikel
|
| 4 |
Combination therapy with immune checkpoint inhibitors and denosumab improves clinical outcomes in non-small cell lung cancer with bone metastases
|
Asano, Yohei
|
|
|
193 |
C |
p.
|
artikel
|
| 5 |
Construction and validation of a clinical differentiation model between peripheral lung cancer and solitary pulmonary tuberculosis
|
Gao, Xukun
|
|
|
193 |
C |
p.
|
artikel
|
| 6 |
Contents
|
|
|
|
193 |
C |
p.
|
artikel
|
| 7 |
Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]
|
Takeda, Masayuki
|
|
|
193 |
C |
p.
|
artikel
|
| 8 |
Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing
|
Mahmood, Kamran
|
|
|
193 |
C |
p.
|
artikel
|
| 9 |
Evaluation of chest CT-scans following lung stereotactic ablative radiotherapy: Challenges and new insights
|
De Bruycker, Aurélie
|
|
|
193 |
C |
p.
|
artikel
|
| 10 |
Exploring the use of circulating tumor DNA for mutational signature analysis
|
Ernst, Sophie M.
|
|
|
193 |
C |
p.
|
artikel
|
| 11 |
Imaging in pleural Mesothelioma: A review of the 16th International Conference of the International Mesothelioma Interest Group
|
Armato III, Samuel G.
|
|
|
193 |
C |
p.
|
artikel
|
| 12 |
Immune checkpoint inhibition in early-stage non-small cell lung cancer
|
Cuppens, Kristof
|
|
|
193 |
C |
p.
|
artikel
|
| 13 |
Impact of number of dissected lymph nodes on recurrence and survival following thoracoscopic segmentectomy for clinical stage I non-small cell lung cancer
|
Huang, Lin
|
|
|
193 |
C |
p.
|
artikel
|
| 14 |
In response to “On the Hispanic paradox in lung cancer”
|
Arrieta, Oscar
|
|
|
193 |
C |
p.
|
artikel
|
| 15 |
Integrative oncology for patients with lung cancer: A prospective pragmatic controlled trial
|
Ben-Arye, Eran
|
|
|
193 |
C |
p.
|
artikel
|
| 16 |
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study
|
Borghaei, Hossein
|
|
|
193 |
C |
p.
|
artikel
|
| 17 |
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
|
Saw, Stephanie P.L.
|
|
|
193 |
C |
p.
|
artikel
|
| 18 |
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06–2018 study)
|
Amari, Lyria
|
|
|
193 |
C |
p.
|
artikel
|
Tijdschrift beschrijving